Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner's inventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/01/12 | $30,000,000 | Series C |
BioStar Ventures Domain Associates Essex Woodlands Morgenthaler | undisclosed |
| 12/04/12 | $10,000,000 | Series C |
BioStar Ventures Domain Associates Essex Woodlands Morgenthaler Western Technology Investment | undisclosed |
| 10/21/13 | $10,000,000 | Series D |
Morningside Group | undisclosed |
